These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 467352)

  • 1. Effect of 1 alpha-hydroxyvitamin D3 in rats with experimental renal osteodystrophy.
    Kawaguchi Y; Kawashima H; Ueno K; Izawa Y; Makita T; Kurozumi S; Hashimoto Y; Yamamoto M; Kimura Y; Imamura N; Oda Y; Sakai S; Ogura Y; Kushida K; Inoue T
    Endocrinol Jpn; 1979 Jun; 26(Suppl):73-9. PubMed ID: 467352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 1 alpha-hydroxyvitamin D3 on experimental uremic renal osteodystrophy in rats induced by Na-sulfacetylthiazole.
    Okano K; Nakai R; Tomori T; Yoshikawa M
    Endocrinol Jpn; 1978 Dec; 25(6):553-9. PubMed ID: 751801
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy.
    Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T
    Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 1 alpha-hydroxyvitamin D3 in children with renal osteodystrophy associated with hemodialysis.
    Chan JC; Oldham SB; DeLuca HF
    J Pediatr; 1977 May; 90(5):820-4. PubMed ID: 853343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy].
    Minatoguchi T
    Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947
    [No Abstract]   [Full Text] [Related]  

  • 12. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S; Olgaard K
    Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgically induced uremia in rats. I: Effect on bone strength and metabolism.
    Jablonski G; Klem KH; Attramadal A; Dahl E; Rønningen H; Gautvik KM; Haug E; Gordeladze JO
    Biosci Rep; 1993 Oct; 13(5):275-87. PubMed ID: 8142613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.
    Langman CB; Mazur AT; Baron R; Norman ME
    J Pediatr; 1982 May; 100(5):815-20. PubMed ID: 7069549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].
    Albertazzi A; Palmieri PF; Del Rosso G; Spisni C; Evangelista M
    Minerva Nefrol; 1980; 27(4):631-3. PubMed ID: 7254690
    [No Abstract]   [Full Text] [Related]  

  • 19. The kidney as an endocrine organ involved in the function of vitamin D.
    DeLuca HF
    Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.